|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Venook AP, Weiser MR and Tepper JE:
Colorectal cancer: All hands on deck. Am Soc Clin Oncol Educ Book.
34:83–89. 2014. View Article : Google Scholar
|
|
3
|
Mayer RJ, Venook AP and Schilsky RL:
Progress against GI cancer during the American Society of Clinical
Oncology's first 50 years. J Clin Oncol. 32:1521–1530. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rescher U and Gerke V: Annexins - unique
membrane binding proteins with diverse functions. J Cell Sci.
117:2631–2639. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim LH and Pervaiz S: Annexin 1: The new
face of an old molecule. FASEB J. 21:968–975. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ydy LR, do Espírito Santo GF, de Menezes
I, Martins MS, Ignotti E and Damazo AS: Study of the Annexin A1 and
its associations with carcinoembryonic antigen and mismatch repair
proteins in colorectal cancer. J Gastrointest Cancer. 47:61–68.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Duncan R, Carpenter B, Main LC, Telfer C
and Murray GI: Characterisation and protein expression profiling of
annexins in colorectal cancer. Br J Cancer. 98:426–433. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okano M, Kumamoto K, Saito M, Onozawa H,
Saito K, Abe N, Ohtake T and Takenoshita S: Upregulated Annexin A1
promotes cellular invasion in triple-negative breast cancer. Oncol
Rep. 33:1064–1070. 2015.PubMed/NCBI
|
|
9
|
Sato Y, Kumamoto K, Saito K, Okayama H,
Hayase S, Kofunato Y, Miyamoto K, Nakamura I, Ohki S, Koyama Y, et
al: Upregulated Annexin A1 expression in gastrointestinal cancer is
associated with cancer invasion and lymph node metastasis. Exp Ther
Med. 2:239–243. 2011.PubMed/NCBI
|
|
10
|
Wang Y, Serfass L, Roy MO, Wong J, Bonneau
AM and Georges E: Annexin-I expression modulates drug resistance in
tumor cells. Biochem Biophys Res Commun. 314:565–570. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takahashi K, Tanaka M, Inagaki A,
Wanibuchi H, Izumi Y, Miura K, Nagayama K, Shiota M and Iwao H:
Establishment of a 5-fluorouracil-resistant triple-negative breast
cancer cell line. Int J Oncol. 43:1985–1991. 2013.PubMed/NCBI
|
|
12
|
Anbalagan D, Yap G, Yuan Y, Pandey VK, Lau
WH, Arora S, Bist P, Wong JS, Sethi G, Nissom PM, et al: Annexin-A1
regulates microRNA-26b* and microRNA-562 to directly target NF-κB
and angiogenesis in breast cancer cells. PLoS One. 9:e1145072014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000.PubMed/NCBI
|
|
14
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gardner LB, Li Q, Park MS, Flanagan WM,
Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through
regulation of p27 expression. J Biol Chem. 276:7919–7926. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation
of hypoxia inducible factor 1 alpha and 2 alpha in operable
non-small cell lung cancer to angiogenic/molecular profile of
tumours and survival. Br J Cancer. 85:881–890. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo
C, Han S, Liu J, Sun S, Han Z, et al: Hypoxia-inducible factor-1
alpha contributes to hypoxia-induced chemoresistance in gastric
cancer. Cancer Sci. 99:121–128. 2008.PubMed/NCBI
|
|
22
|
An WG, Kanekal M, Simon MC, Maltepe E,
Blagosklonny MV and Neckers LM: Stabilization of wild-type p53 by
hypoxia-inducible factor 1alpha. Nature. 392:405–408. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ravi R, Mookerjee B, Bhujwalla ZM, Sutter
CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL and Bedi A:
Regulation of tumor angiogenesis by p53-induced degradation of
hypoxia-inducible factor 1alpha. Genes Dev. 14:34–44.
2000.PubMed/NCBI
|
|
24
|
Chen J, Ding Z, Peng Y, Pan F, Li J, Zou
L, Zhang Y and Liang H: HIF-1α inhibition reverses multidrug
resistance in colon cancer cells via downregulation of
MDR1/P-glycoprotein. PLoS One. 9:e988822014. View Article : Google Scholar : PubMed/NCBI
|
